News & articles

November 18, 2014 Myelofibrosis patient Bill Erickson is in the news for his support of the Cap the Copay Coalition, an Illinois initiative which seeks to reduce the costs people taking specialty tier medications must pay out of pocket. MPN Research Foundation is part of the Coalition, which is seeking help from some Illinois lawmakers… Read More »NOV. 2014 UPDATE ON CAP THE COPAY

The FDA has granted Fast Track designation to PRM-151 for the treatment of myelofibrosis (MF), a serious, life-limiting cancer characterized by fibrosis of the bone marrow. This Fast Track designation covers Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, and Post-Essential Thrombocythemia Myelofibrosis. The FDA grants Fast Track designation to a product that is intended to treat a… Read More »2014 PROMEDIOR FAST TRACK

Geron Corporation (Nasdaq: GERN) announced on November 3rd that the FDA)has removed the full clinical hold on their investigational new drug application for imetelstat. In addition, the FDA stated that Geron’s proposed clinical development plan for imetelstat that is focused on high-risk myeloid malignancies, such as myelofibrosis (MF), is acceptable. Click here to read the full… Read More »2014 FDA REMOVES CLINICAL HOLD ON GERON’S IMETELSTAT

October 2, 2014 Shire Japan KK announced that the Japanese MHLW (Ministry of Health, Labour and Welfare) has approved AGRYLIN® (anagrelide hydrochloride) for the treatment of essential thrombocythemia. AGRYLIN went through clinical trials in response to a request from MHLW in May 2010 based on the results of its “Study Group on Unapproved and Off-Label… Read More »2014 SHIRE APPROVED FOR AGRYLIN

By Therese Flaherty My husband Tim, a firefighter for 33 years with the Portland Fire Department, an avid gardener, outdoorsmen and family man passed away August 30, 2011 at only 63 years old, following a courageous fight against Myelofibrosis. The MPN community lost a hero that day. And I lost my husband and best friend.… Read More »2014 WHY WE CREATED TIMS RUN

By past MPN Research Foundation grantee (MF Challenge) Pearlie K. Burnette PhD, PharmD, Moffitt  Cancer Center The immune system is made up of many types of cells and secreted factors that act together to defend against infections and remove damaged tissues. In the case of cancer, normal cells and cancer cells appear different, and thus,… Read More »IMMUNOTHERAPY: FOCUS AREA THREE

By John D Crispino, PhD, Robert I. Lurie, MD and Lora S. Lurie Professor I’m often asked to explain what exactly is bone marrow fibrosis. In non-technical terms, it is a condition in which the place where blood cell precursors live becomes unfriendly. You can think of the bone marrow niche as a comfortable bed,… Read More »FIBROSIS: FOCUS AREA TWO

September 24, 2014 Dr Angela Fleischman has opened a MPN research laboratory at University of California – Irvine. More information on the lab can be found here. She is looking for help collecting blood samples of MPN patients for a study of the MPN inflammatory processes. If you are an MPN patient in Southern California and are… Read More »SAMPLES SOUGHT BY ANGELA FLEISCHMAN, UC IRVINE

September 18, 2014 Gilead Sciences, Inc is sponsoring a qualitative research study to evaluate the Modified Myeloproliferative Neoplasms Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) in an electronic format. The study is being conducted by Evidera, Inc., on Gilead’s behalf, and involves the recruitment of up to 25 participants with myelofibrosis.Researchers are currently seeking… Read More »2014 MPN STUDY BY GILEAD AND EVIDERA

September 15, 2014 By Jen, mother of an Essential Thrombocythemia patient This is a tattoo I got for my daughter who has an MPN. Two years ago she was diagnosed with essential thrombocythemia at age five. Despite the shock of the diagnosis, she is a happy seven year old and is doing well. Emotionally, as… Read More »JEN’S CAREGIVER STORY – ET